ArticleImmunology1995
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis.
Article in Immunology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 179 citations in OpenAlex.
- Article
- The Absence of CXCL10 Activity Does Not Affect the Capability of CD8Microorganisms · 2024Article
- The Toxoplasma Effector GRA4 Hijacks Host TBK1 to Oppositely Regulate Anti-T. Gondii Immunity and Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Effective factors in the pathogenesis ofHeliyon · 2024Review
- Animal Models for Toxoplasma gondii Infection.Current protocols · 2023Article
- Chronic infection by atypicalBrain, behavior, & immunity - health · 2023Article
- Dense granule protein 3 ofFrontiers in immunology · 2023Article
- Chronic Toxoplasma gondii infection contributes to perineuronal nets impairment in the primary somatosensory cortex.Parasites & vectors · 2022Article
- IFN-γ stimulated murine and human neurons mount anti-parasitic defenses against the intracellular parasite Toxoplasma gondii.Nature communications · 2022Article
- Article
- Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection againstVaccines · 2022Article
- Human MHC class I molecule, HLA-A2.1, mediates activation of CD8Frontiers in immunology · 2022Article
- Forward Genetics in Apicomplexa Biology: The Host Side of the Story.Frontiers in cellular and infection microbiology · 2022Review
- Genetic mapping reveals Nfkbid as a central regulator of humoral immunity to Toxoplasma gondii.PLoS pathogens · 2021Article
- Neurological and Neurobehavioral Disorders Associated withJournal of parasitology research · 2021Review
- Targeted Transcriptomic Analysis of C57BL/6 and BALB/c Mice During Progressive ChronicFrontiers in cellular and infection microbiology · 2021Article
- An Unusual MHC Molecule Generates Protective CD8+ T Cell Responses to Chronic Infection.Frontiers in immunology · 2020Article
- Influence of the Host and Parasite Strain on the Immune Response DuringFrontiers in cellular and infection microbiology · 2020Review
- Robust Control of a Brain-Persisting Parasite through MHC I Presentation by Infected Neurons.Cell reports · 2019Article
- Immunogenicity of a Virus-Like-Particle Vaccine Containing Multiple Antigenic Epitopes ofFrontiers in immunology · 2019Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Control of resistance to cyst burden following per-oral infection with Toxoplasma gondii has been mapped previously to a region of mouse chromosome 17 of approximately 140 kb. This region is contiguous with and contains the class I gene, Ld. Resistance to development of toxoplasmic encephalitis has also been reported to be controlled by genes in this region of H-2. TNF-alpha, D and L genes, as well as unidentified genes, are also in this region. The work described here was performed to identify definitively the gene(s) in this 140 kb region that confers resistance to cysts and encephalitis. The study demonstrates that relative resistance to T. gondii organisms and cyst burden in brain, and toxoplasmic encephalitis, 30 days following per-oral T. gondii infection is correlated absolutely with the presence of the Ld gene in inbred, recombinant, mutant and C3H.Ld transgenic mice. Mice with the Ld gene had lower cyst burdens and less encephalitis than those without the Ld gene. Specifically, 30 days after infection mice with the Ld gene had minimal perivascular inflammation and meningeal inflammation and very few Toxoplasma cysts or organisms in immunoperoxidase-stained preparations of their brains. Mice without the Ld gene had a similar pattern of inflammation, but in addition they had collections of inflammatory cells in the brain parenchyma. Free tachyzoites were found within these foci of inflammation and cysts were present in these areas as well as in contiguous areas without inflammatory cells. There were CD4+ and CD8+ T lymphocytes in the areas of inflammation and throughout the brain parenchyma. Mice that were resistant to cysts and encephalitis had little detectable brain cytokine mRNA expression, while mice that were susceptible had elevated levels of mRNA for a wide range of cytokines, consistent with their greater amounts of inflammation. The present work definitively demonstrates that a Ld-restricted response decreases the number of organisms and cysts within the brain and thereby limits toxoplasmic encephalitis and levels of interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2), IL-6, IL-10, transforming growth factor-beta (TGF-beta), IL-1 alpha, IL1 beta and macrophage inhibiting protein (MIP) mRNA in the brain 30 days after per-oral infection.
Indexed as
Identifiers
7558130PMC1383915W1482306167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.